Eli Lilly and Company (LLY) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
Eli Lilly (LLY) Q2 2026: Obesity Portfolio Adds $6.8B, Fueling 48% Revenue Surge and Global Expansion
August 05, 2026
24
LLY Q4 2025: Incretin Portfolio Drives 91% Key Product Growth, Setting Stage for $80B+ 2026
June 15, 2026
25
LLY Q1 2026: Dual Agonist Uptake Drives 53% OUS Market Share, Expanding Global Obesity Franchise
April 30, 2026
23
Eli Lilly (LLY) Q3 2025: Incretin Portfolio Drives 54% Revenue Growth, Orforglipron Scales Global Ambition
October 30, 2025
23
Lilly (LLY) Q2 2025: GLP-1 Franchise Powers 38% Top-Line Surge, Capacity Expansion to 1.8x Fuels Long-Term Growth
August 07, 2025
21
Eli Lilly (LLY) Q1 2025: 45% Revenue Surge as Obesity and Diabetes Pipeline Redefines Growth Trajectory
June 10, 2025

Browse all companies